Maa: Australia
Kieli: englanti
Lähde: Department of Health (Therapeutic Goods Administration)
Tetanus toxoid, Quantity: 40 IU; Diphtheria toxoid, Quantity: 20 IU; Poliovirus, Quantity: 80 DAgU; Pertussis fimbriae 2 + 3, Quantity: 5 microgram; Haemophilus influenza type B polyribose ribitol phosphate, Quantity: 3 microgram; Pertussis toxoid, Quantity: 20 microgram; Pertussis filamentous haemagglutinin, Quantity: 20 microgram; hepatitis B surface antigen, Quantity: 10 microgram; Pertactin, Quantity: 3 microgram
Maxx Pharma Pty Ltd
Injection, suspension
Excipient Ingredients: aluminium; water for injections; dibasic sodium phosphate; monobasic sodium phosphate
Intramuscular
10
(S4) Prescription Only Medicine
VAXELIS (DTPa5-HB-IPV-Hib) is indicated for primary and booster vaccination in infants and toddlers from the age of 6 weeks, against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive diseases caused by Haemophilus influenzae type b (Hib).,The use of Vaxelis should be in accordance with official recommendations.
Visual Identification: cloudy, white to off-white suspension; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 48 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert
Registered
2022-03-23
Vaxelis ™ 1 VAXELIS™ CONSUMER MEDICINE INFORMATION (CMI) SUMMARY The full CMI on the later pages has more details. If you are worried about having your child receive this vaccine, speak to your child’s doctor or nurse. This medicine is new or being used differently. Please report side effects. See the full CMI for further details. 1. WHY IS MY CHILD RECEIVING VAXELIS? Vaxelis is a vaccine given to help protect your child against diphtheria, tetanus (lockjaw), pertussis (whooping cough), hepatitis B, polio and Hib (_Haemophilus influenzae_ type b). For more information, see Section 1. Why is my child receiving Vaxelis? in the full CMI. 2. WHAT SHOULD I KNOW BEFORE MY CHILD RECEIVES VAXELIS? Do not use if your child has had shortness of breath or swelling of the face after a previous dose of Vaxelis, has ever had an allergic reaction to Vaxelis or any of the ingredients listed at the end of the CMI, has suffered from a severe reaction affecting the brain (encephalopathy) within 7 days of a prior dose of a pertussis vaccine or has an uncontrolled condition or severe illness affecting the brain and nervous system (uncontrolled neurologic disorder) or uncontrolled epilepsy. TALK TO YOUR DOCTOR IF YOUR CHILD HAS OR HAS HAD ANY OTHER MEDICAL CONDITIONS OR IS TAKING ANY OTHER MEDICINES. For more information, see Section 2. What should I know before my child receives Vaxelis? in the full CMI. 3. WHAT IF MY CHILD IS TAKING OTHER MEDICINES? Some medicines may interfere with Vaxelis and affect how it works. A list of these medicines is in Section 3. What if my child is taking other medicines? in the full CMI. 4. HOW WILL MY CHILD RECEIVE VAXELIS? Vaxelis is given by your child’s doctor or nurse as an injection into the muscle. More instructions can be found in Section 4. How will my child receive Vaxelis? in the full CMI. 5. WHAT SHOULD I DO AFTER MY CHILD RECEIVES VAXELIS? THINGS YOU SHOULD DO Tell your child’s doctor or nurse immediately after your child receives the vaccine and if your child has • difficulty i Lue koko asiakirja
Product and Consumer Medicine Information Licence ------------------------- ACCESS TERMS FOR PRODUCT INFORMATION AND CONSUMER MEDICINE INFORMATION DOCUMENTS ("LICENCE") PARTIES YOU or YOUR means any legal person or entity who accesses or downloads a PI Document or CMI Document from Our website and US, WE or OUR means the COMMONWEALTH OF AUSTRALIA as represented by the THERAPEUTIC GOODS ADMINISTRATION ABN 40 939 406 804 of 136 Narrabundah Lane, Symonston ACT 2609, Australia. OPERATIVE PROVISIONS * NATURE OF AGREEMENT * 1.1 This Licence specifies the terms and conditions of Your access and use of PI Documents and CMI Documents made available to the general public by Us via Our website. * 1.2 You acknowledge and agree that accessing PI Documents or CMI Documents in accordance with this Licence is beneficial to You because it provides You with product information about therapeutic goods and is beneficial to Us because it assists Us in our portfolio responsibilities. * TERMS OF ACCESS * 2.1 We grant to You a perpetual, non-exclusive, royalty-free, world-wide, irrevocable and non-transferable licence to download, store in cache, display, print and copy a single copy or part of a single copy of a PI Document or CMI Document made available via Our website. * 2.2 If You wish to use any PI Document or CMI Document for purposes other than those specified in clause 2.1 of this Licence, You must seek the permission of the Sponsor. * 2.3 We may remove a PI Document or CMI Document from Our website at any time in Our sole discretion. * EXCLUSION OF LIABILITY * 3.1 You acknowledge and agree that You are responsible for making Your own enquiries to determine whether any PI Document or CMI Document is accurate, up to date and fit for Your purposes. * 3.2 The PI Document or CMI Document is provided to You for the purpose of disseminating health information free of charge for the benefit of the public. This Licence and any PI Document or CMI Document made available to You via Our website is not a substitute fo Lue koko asiakirja